Möchten Sie immer auf dem neuesten Stand bleiben?

Des études de phase 2 sur le lunsekimig ont atteint les critères d’évaluation principaux et secondaires clés dans deux maladies respiratoires

Phase 2 studies of lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in two chronic respiratory conditions.

Candidate has potential to be a first-in-class treatment offering biologic-like disease control from an oral small moleculeRegulatory submission preparation and entry into the clinic is expected in H1...

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...

Washington, DC, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) applauds Congress for protecting $33.5 million in funding for the Centers for Disease Control...

KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome

Washington, DC, Oct. 29, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) today calls on Congress to take immediate action to make health insurance more affordable by...